Semax for Migraine: What the Evidence Actually Shows (2026)

An FDA advisory committee voted in July 2026 to recommend Semax for pharmacy compounding — over the objection of FDA's own reviewers. Here is what the migraine research behind this peptide actually consists of.

Semax has been circulating in the wellness and "peptide therapy" market for years, and it received renewed attention in July 2026 when an FDA advisory committee reportedly voted to recommend it for the list of substances that compounding pharmacies may legally use. If you have migraine and you've seen Semax discussed online, it's worth understanding what the actual research base looks like — and what that decision does and does not mean.

The short version: the clinical evidence for Semax in migraine consists of a single small study from 1996 involving twelve people, and by FDA's assessment, that study did not show the drug worked for most of them.

What Semax Is

Semax is a synthetic heptapeptide — a chain of seven amino acids — with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analogue of the ACTH(4-10) fragment of adrenocorticotropic hormone, modified so that it lacks the hormonal corticotropic and melanotropic activity of the parent protein while retaining neurobehavioral effects. The C-terminal Pro-Gly-Pro sequence is thought to make the peptide more resistant to breakdown by peptidases.

Semax is a registered drug in Russia, where it is available as 0.1% and 1% nasal drops. It is not an FDA-approved drug in the United States, is not a component of any FDA-approved drug product, and has no monograph in the United States Pharmacopeia, the European Pharmacopoeia, the Japanese Pharmacopoeia, or the International Pharmacopoeia.

Part One: The State of the Science

FDA scientists prepared a detailed evaluation of Semax as part of the agency's review of whether it should be permitted in pharmacy compounding. The document is dated May 11, 2026 and was released publicly ahead of the July 2026 advisory committee meeting. In preparing it, FDA searched PubMed, Embase, the Cochrane Database of Systematic Reviews, ClinicalTrials.gov, professional healthcare organization websites, and additional clinical databases.

The Migraine Evidence: One Study, Twelve People

FDA identified exactly one clinical study evaluating Semax for migraine — Koroleva et al., published in 1996 — and stated it was unable to find any additional references on the topic.

Here is what that study did:

And here is what it found:

• Total MPST score fell from 78% before dosing to 32% after.
• 4 of the 12 participants (33%) reported their headache pain stopped, 90 to 120 minutes after administration.
• In the remaining 8 participants, the authors described the effect as weaker: pain was reduced in severity but was not eliminated.

FDA catalogued substantial methodological problems with the study:

• No blinding
• No control group
• Small sample size
• No reporting of the actual numerical scores or standard deviations behind the rating scales
• No description of the MPST scale itself — FDA noted the authors did not describe it, cited no source for it, and the agency could not locate additional information about it independently
• No baseline information about the migraines being treated, such as headache intensity, severity, associated symptoms, or whether the headaches were unilateral or bilateral
• Insufficient reporting of study design and conduct generally

FDA's conclusion on migraine was direct: there is insufficient evidence of effectiveness to support use of Semax for headache pain in people with migraine, and the results of this single small, uncontrolled, open-label study showed that Semax was not effective in resolving headache pain for the majority of participants.

FDA also noted that professional society treatment guidelines for migraine (citing Ailani et al. 2021) do not discuss Semax at all.

The Same 1996 Study Also Looked at Facial Pain — and Found Less

The Koroleva study enrolled three pain groups, not just migraine. The other two are informative about the drug's analgesic properties generally:

Notably, the study's own authors concluded that no significant changes in trigeminal somatosensory evoked potentials were observed after a single intranasal dose, and that this indicated Semax does not exhibit analgesic activity by itself.

FDA reached the same conclusion for trigeminal neuralgia as it did for migraine: insufficient evidence of effectiveness, from a single small, uncontrolled, open-label study in which Semax was not effective in resolving pain for the majority of participants.

The Other Proposed Uses Fare No Better

FDA also evaluated Semax for cerebral ischemia. The only reference available was Cherkasova et al. 2002 — a conference meeting abstract for which no full published article could be located. The abstract described giving intranasal Semax to an unspecified number of human subjects with chronic ischemic brain disease, did not report full laboratory results, and did not discuss clinical function before or after treatment.

FDA identified additional Semax research on cerebral ischemia published in Russian. Under federal regulation (21 CFR 10.20(c)(2)), material submitted in a foreign language must be accompanied by a verified English translation. Because the full references were not available in English, they were not considered as part of the evaluation. This is a real limitation in interpreting the record: a body of Russian-language clinical literature on Semax exists, but it was not before FDA in a form the agency could assess, and this article makes no claim about what it does or does not show.

Animal Research: Promising Signals, Important Caveats

The nonclinical picture is more active than the clinical one. In rodents, Semax has shown neuroprotective and neurotrophic properties, anticoagulant and antithrombotic effects, analgesic effects, and antidepressant- and anxiolytic-like effects. In rat models of focal and global cerebral ischemia, Semax reduced ischemic damage.

Two findings from the animal analgesia research deserve attention from anyone considering Semax for pain.

1. Route of administration mattered — and not in Semax's favor. In a study by Manchenko et al. (2012), intraperitoneal Semax produced dose-dependent increases in pain threshold in rats across a range of doses. The same doses delivered intranasally did not produce analgesia at all. Intranasal is the only route discussed in the human literature FDA reviewed, and it is one of the two routes Semax is marketed in.

2. The mechanism is poorly understood and includes a flag. The opioid antagonist naloxone did not block Semax's analgesic effect, while the serotonin antagonist cyproheptadine did, leading researchers to propose a serotonergic mechanism. But Semax also potentiated amphetamine-induced dopamine release in the striatum in mice. FDA specifically identified this as concerning, because increased striatal dopaminergic tone is a response typically produced by drugs of abuse such as cocaine. FDA noted that no nonclinical studies were submitted or identified that would inform whether Semax has reinforcing or addictive properties.

What Safety Data Exists

This is the thinnest part of the record.

• No human pharmacokinetic studies were found for Semax by any route of administration.
• No safety data at all exists for subcutaneous injection — one of the two routes proposed for compounding. The only route discussed in the literature is intranasal.
• No acute toxicity studies, no repeat-dose toxicity studies, and no developmental or reproductive toxicity studies were submitted or identified. No adequate two-year carcinogenicity study or weight-of-evidence carcinogenicity analysis exists.
• Total documented human exposure across all studies FDA located: roughly 33–47 healthy adults, 69 adults with medical conditions, and 451 children. Three of these references were professional society meeting abstracts without full published data. In one reference the authors reported no adverse events; in the others, adverse events were simply not discussed.
• FDA searched its Adverse Event Reporting System (FAERS) through December 3, 2025 and found one report: a consumer who reported ocular pain and eye burning in May 2024 after using Semax 0.1% nasal drops purchased online, reported hospitalization following the exposure, and reported that the eye pain had not resolved as of May 2025.

Product Quality: What's in the Bottle Is Unknown

FDA concluded that both Semax free base and Semax acetate are not well-characterized from a physical and chemical standpoint, for two reasons.

The first is naming. "Semax" is a common name, not a United States Adopted Name, and it does not follow INN, IUPAC, or USAN nomenclature standards. FDA noted that it has encountered multiple salts and derivatives — including different active moieties — sold commercially under the same common name. The free base and the acetate salt are different active pharmaceutical ingredients with potentially different safety and efficacy profiles. Tellingly, the two nomination packages submitted to FDA were themselves internally inconsistent: certificates of analysis referred to one substance in the title and a different one by CAS number and molecular formula.

The second is missing quality control data. Testing results for impurities, aggregates, microbial bioburden, and bacterial endotoxins were not found in the certificates of analysis provided or in the published literature. Bacterial endotoxin testing is a critical quality attribute for any injectable product. For the proposed nasal spray, no information was available about the container-closure system or pump — components that directly determine dose delivery, spray pattern, and droplet size.

For context on the current market: FDA's search found that no outsourcing facility has reported compounding drug products containing Semax since 2019, and a search did not identify pharmacies marketing Semax products. What FDA did find were wellness clinics, medical concierge services, regenerative medicine clinics, and online retailers selling Semax nasal spray and injectable products — marketed for anxiety, depression, memory and attention, stroke, nerve regeneration, diabetic neuropathy, ADHD, opioid withdrawal, ALS, Parkinson's disease, Alzheimer's disease, optic nerve atrophy, pain, and gastric protection. None of the websites searched indicated whether their products contained the free base, a salt, or an ester.

Part Two: The FDA Decision and What It Means

What Was Actually Being Decided

This is the single most misunderstood aspect of the July 2026 news, so it's worth being precise.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) was not considering whether to approve Semax as a drug. It was considering whether Semax should be added to the Section 503A Bulk Drug Substances List — the roster of ingredients that a licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, may use when compounding a medication for an individual patient with a valid prescription.

These are entirely different things. FDA approval requires demonstrating safety and efficacy through controlled clinical trials. Inclusion on the 503A Bulks List requires FDA to balance four criteria set out at 21 CFR 216.23(c): whether the substance is well characterized physically and chemically, whether it has been used historically in compounding, available evidence of effectiveness or lack of effectiveness, and safety concerns.

FDA has also said so directly. In its January 2025 guidance on this process, the agency wrote that its evaluation of a substance for the 503A bulks list is "necessarily, far less rigorous and less comprehensive" than its review of drugs in the new drug approval process.

Semax was evaluated for three specific uses: cerebral ischemia, migraine, and trigeminal neuralgia. The proposed products were intranasal spray or subcutaneous injection at 7,500 µg/mL or 1,000 µg/mL.

One procedural oddity is worth noting: the two nominations for Semax were withdrawn by their nominators. FDA elected to proceed with the evaluation on its own initiative.

FDA Scientists Recommended Against It

In the briefing materials prepared for the committee, FDA staff proposed that neither Semax free base nor Semax acetate be included on the 503A Bulks List.

The agency's overall conclusion was that the physicochemical characterization, information on historical use, lack of evidence of effectiveness, and safety information all weighed against inclusion. On effectiveness specifically, FDA found only two usable references across all three proposed indications, both with insufficient detail on study design and conduct, both limited by small sample size, and both demonstrating lack of effectiveness. FDA also emphasized that cerebral ischemia, migraine, and trigeminal neuralgia are all serious conditions for which FDA-approved treatments already exist. (For migraine specifically, see our plain-English guide to the latest migraine medications.)

The Advisory Committee Disagreed

At its meeting on July 24, 2026, the PCAC is reported to have voted to recommend that Semax — both free base and acetate forms — be added to the 503A Bulks List, against FDA staff's written recommendation.

Two things about this vote matter for interpreting it.

No new clinical evidence on migraine has come to light. FDA's search identified one migraine study, and no additional trial has been published or reported since. Press accounts of the meeting indicate the vote was close and that supporting members' reasoning centered on the breadth of preclinical animal research and the absence of approved alternatives with comparable mechanisms, rather than on any new clinical finding. We have not seen any report of new migraine data being presented.

A favorable vote is not a statement that the drug works. The committee was answering a compounding-access question under a four-factor balancing test, not certifying efficacy — and as noted above, 21 CFR 216.23(d) makes explicit that listing does not establish safety or efficacy.

What This Changes for Consumers: Nothing, Yet

PCAC recommendations are advisory and non-binding. FDA is not required to follow them.

If FDA does choose to act on the recommendation, adding a substance to the 503A Bulks List requires notice-and-comment rulemaking — a proposed rule, a public comment period, agency response to comments, and a final rule. FDA has stated that only after a final rule is published will drug products compounded with a listed substance be eligible for the Section 503A exemptions. Nothing about the legal status of Semax changed on July 24, 2026.

Where that leaves Semax today requires one point of precision. Under Section 503A, a bulk drug substance that is not the subject of an applicable USP or NF monograph and is not a component of an FDA-approved drug product cannot be used in compounding unless it appears on the list codified at 21 CFR 216.23. Semax meets none of those three conditions. FDA's guidance states that a drug product compounded from a substance meeting none of them is not eligible for the Section 503A exemptions and may violate the FD&C Act.

There is one qualifier worth knowing about. FDA operates an interim policy under which it does not intend to take action against a state-licensed pharmacy, federal facility, or licensed physician compounding with a not-yet-listed bulk substance if several conditions are all met — including that the substance appears in "Category 1" on FDA's website, that its manufacturers are registered under section 510, and that it is accompanied by a valid certificate of analysis. We have not been able to confirm Semax's current category status from a primary FDA source, and note that FDA's briefing document records that both Semax nominations were withdrawn. Readers should not assume either that Semax currently falls within this enforcement-discretion policy or that it does not.

That means Semax products currently sold online in the United States are not compounded prescription medications prepared under 503A. They are being sold outside that framework — FDA's search found one online retailer offering Semax labeled "for research purposes only" while listing nasal spray and subcutaneous injection as common methods of administration — and the quality-control gaps FDA identified apply directly to them. The uncertainty about which chemical form is in the product, the absence of impurity and endotoxin testing, the aggregation and immunogenicity questions, and the unknown container-closure characteristics of nasal spray devices are not hypothetical regulatory concerns. They describe what is actually unknown about a product bought from an online vendor today.

The Bottom Line for People with Migraine

The honest summary is that Semax has not been meaningfully studied for migraine. The entire clinical evidence base FDA could identify is one open-label study from 1996 with twelve participants, no control group, no blinding, and a majority of participants whose pain was not resolved. In the same paper's facial-pain arms, the authors concluded the peptide did not appear to have analgesic activity on its own. FDA's search of PubMed, Embase, Cochrane, and ClinicalTrials.gov turned up no controlled trial of Semax for migraine.

The July 2026 advisory vote is a regulatory development, not a scientific one. It reflects a committee's judgment about compounding access under a balancing test — a judgment made on the same thin record, over the objection of FDA's own reviewers.

Meanwhile, there are numerous FDA-approved prescription and over-the-counter products for both the acute treatment and the prevention of migraine — we cover these in detail in our guide to the 2025 migraine treatment guidelines. These have been through controlled trials and carry labeling that describes their risks and interactions — two things FDA specifically noted are absent here.

If you're struggling to find something that works, that's a real and common experience — and it's worth raising with a neurologist or headache specialist, who can speak to options you may not have tried. It is a better path than an unregulated peptide with one 1996 study behind it.